New drug set for approval to treat hand eczema, bringing relief to patients.

Good news for eczema sufferers in the UK – a new cream called delgocitinib has been developed to treat debilitating hand eczema. This medication has shown promising results in trials, reducing itchiness and redness within days with fewer side effects than current treatments offered on the NHS. Hand eczema, which is most common in people who work with irritating chemicals, can leave skin on the hands and wrists cracked and sore.

Delgocitinib, a janus kinase (JAK) inhibitor, is designed to target hand eczema specifically and is set to become the first treatment of its kind available on the NHS. Results from a recent trial involving 500 participants have shown that delgocitinib is more effective and has fewer side effects than steroid creams or other medications currently used for hand eczema. Health officials are likely to approve the rollout of this drug based on the positive study results, offering hope to the estimated 14 percent of the UK population who suffer from hand eczema.

Patients like 21-year-old radio journalist George Icke, who struggles with unsightly and painful eczema flare-ups on his hands and wrists, are hopeful that delgocitinib will make a significant difference in their lives. With its potential to improve both physical symptoms and emotional well-being, this new cream could provide relief for thousands of patients in the UK next year.